MindMaze Therapeutics Holding SA (SWX: MMTX)
Health Care · Biotechnology · CH
CHF0.14
-5.55% today · -92.7% 1Y
MindMaze Therapeutics Holding SA (SWX: MMTX) operates in the Biotechnology industry within the Health Care sector. The company is valued at $28.43M and employs 10 people.
Over the last twelve months the share price has lost 92.7%, trading between 0.13 and 2.92.
Tweenvest scores MindMaze Therapeutics Holding SA across four factors: quality 58/100. Its strongest factor is quality.
MMTX price history
Key figures
- Market cap
- $28.43M
- Revenue (TTM)
- $1.48M
- P/E
- —
- EPS
- -0.48
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- CHF2.92
- 52-week low
- CHF0.13
- Avg volume (3M)
- —
- Shares outstanding
- 169.99M
- Employees
- 10
- Next earnings
- —
About MindMaze Therapeutics Holding SA
MindMaze Therapeutics Holding SA operates as a commercial-stage biopharmaceutical and neurotechnology company in Asia, the United States, Switzerland, rest of Europe, and internationally. The company offers MindPod system, a supervised in-clinic neurorehabilitation system designed to initiate and intensify the recovery journey; MindMotion GO, which extends protocolized neurotherapeutics into outpatient and home settings; MindMotion Companion, an application that manages prescription, monitoring and documentation across MindMaze Therapeutics’ neurotherapeutics ecosystem; and the patient app, a patient-facing mobile application, that supports clinic-to-home continuity by making prescribed therapy easy to follow outside the clinic. It also provides Izar hand therapy device which supports fine motor rehabilitation; Physilog sensor, a wearable inertial sensing device designed to quantify human movement; toaprun, a training for Parkinson’s therapy-reimagined through play. The company was founded in 2012 and is headquartered in Geneva, Switzerland.
- ISIN
- CH1251125998
- Founded
- 2012
- Listed since
- Dec 15, 2025
- Exchange
- SIX Swiss Exchange
- Currency
- CHF
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Mendus AB (publ)OM: IMMU | $28.73M | Skr4.49 | -8.37% |
| Poltreg S.A.WSE: PTG | $28.68M | zł19.30 | +0.78% |
| Biomark Diagnostics Inc.DB: 20B | $28.67M | €0.24 | 0.00% |
| Pelthos Therapeutics Inc.NYSEAM: PTHS | $28.48M | $7.44 | -7.35% |
| Amplia Therapeutics LimitedASX: ATX | $28.42M | AU$0.08 | -1.20% |
| Microbix Biosystems Inc.TSX: MBX | $28.29M | CA$0.30 | +1.72% |
| Edesa Biotech, Inc.NasdaqCM: EDSA | $28.10M | $2.08 | -6.31% |
| ProMIS Neurosciences, Inc.NasdaqCM: PMN | $28.07M | $3.13 | -2.49% |